Design, synthesis and biological evaluation of selective survivin inhibitors

Abstract

The differential distribution between cancer cells and normal adult tissues makes survivin a very attractive cancer drug target. We have previously reported a series of novel selective survivin inhibitors with the most potent compound MX106 reaching nanomolar activity in several cancer cell lines. Further optimization of the MX106 scaffold leads to the discovery of more potent and more selective survivin inhibitors. Various structural modifications were synthesized and their anticancer activities were evaluated to determine the structure activity relationships for this MX106 scaffold. In vitro anti-proliferative assays using two human melanoma cell lines showed that several new analogs have improved potency compared to MX106. Very interestingly, these new analogs generally showed significantly higher potency against P-glycoprotein overexpressed cells compared with the corresponding parental cells, suggesting that these compounds may strongly sensitize tumors that have high expressions of the P-glycoprotein drug efflux pumps. Western blotting analysis confirmed that the new MX106 analogs maintained their mechanism of actions by selectively suppressing survivin expression level among major inhibitors of apoptotic proteins and induced strong apoptosis in melanoma tumor cells.

Keywords

selective survivin inhibitors / structure activity relationships / melanoma / human epidermoid carcinoma / colorectal cancer / P-glycoprotein drug efflux pumps

References

[1] Athanasoula KCh, Gogas H, Polonifi K, Survivin beyond physiology: orchestration of multistep carcinogenesis and therapeutic potentials[J]. Cancer Lett, 2014, 347 (2): 175–182

[2] Garg H, Suri P, Gupta JC, Survivin: a unique target for tumor therapy[J]. Cancer Cell Int, 2016, 16: 49

[3] Andersen MH, Svane IM, Becker JC, The universal character of the tumor-associated antigen survivin[J]. Clin Cancer Res, 2007, 13 (20): 5991–5994

[4] Hartman ML, Czyz M. Anti-apoptotic proteins on guard of melanoma cell survival[J]. Cancer Lett, 2013, 331 (1): 24–34

[5] Mita AC, Mita MM, Nawrocki ST, Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics[J]. Clin Cancer Res, 2008, 14 (16): 5000–5005

[6] Carmena M, Wheelock M, Funabiki H, The chromosomal passenger complex (CPC): from easy rider to the godfather of mitosis[J]. Nat Rev Mol Cell Biol, 2012, 13 (12): 789–803

[7] Knauer SK, Mann W, Stauber RH. Survivin’s dual role: an export’s view[J]. Cell Cycle, 2007, 6 (5): 518–521

[8] Altieri DC. Targeting survivin in cancer[J]. Cancer Lett, 2013, 332 (2): 225–228

[9] Chen X, Duan N, Zhang C, Survivin and tumorigenesis: molecular mechanisms and therapeutic strategies[J]. J Cancer, 2016, 7 (3): 314–323

[10] O’Connor DS, Wall NR, Porter AC, A p34 (cdc2) survival checkpoint in cancer[J]. Cancer Cell, 2002, 2 (1): 43–54

[11] Jha K, Shukla M, Pandey M. Survivin expression and targeting in breast cancer[J]. Surg Oncol, 2012, 21 (2): 125–131

[12] Kanwar JR, Kamalapuram SK, Kanwar RK. Targeting survivin in cancer: patent review[J]. Expert Opin Ther Pat, 2010, 20 (12): 1723–1737

[13] Cho HJ, Kim HR, Park YS, Prognostic value of survivin expression in stage III non-small cell lung cancer patients treated with platinum-based therapy[J]. Surg Oncol, 2015, 24 (4): 329–334

[14] Huang YJ, Qi WX, He AN, The prognostic value of survivin expression in patients with colorectal carcinoma: a meta-analysis[J]. Jpn J Clin Oncol, 2013, 43 (10): 988–995

[15] Singh N, Krishnakumar S, Kanwar RK, Clinical aspects for survivin: a crucial molecule for targeting drug-resistant cancers[J]. Drug Discov Today, 2015, 20 (5): 578–587

[16] Tonini G, Vincenzi B, Santini D, Nuclear and cytoplasmic expression of survivin in 67 surgically resected pancreatic cancer patients[J]. Br J Cancer, 2005, 92 (12): 2225–2232

[17] Wang J, Lu Z, Yeung BZ, Tumor priming enhances siRNA delivery and transfection in intraperitoneal tumors[J]. J Control Release, 2014, 178: 79–85

[18] Groner B., Weiss A.Targeting survivin in cancer: novel drug development approaches[J]. BioDrugs: clinical immunotherapeutics, biopharmaceuticals and gene therapy,2014,28 (1): 27–39.

[19] Xiao M, Li W. Recent advances on small-molecule survivin inhibitors[J]. Curr Med Chem, 2015, 22 (9): 1136–1146

[20] Ling X, Cao S, Cheng Q, A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity[J]. PLoS One, 2012, 7 (9): e45571

[21] Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters[J].Nat Rev Cancer, 2002, 2 (1): 48–58

[22] Li W, Zhang H, Assaraf YG, Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies[J]. Drug Resist Updat, 2016, 27: 14–29

[23] Kita A., Nakahara T., Takeuchi M., Kinoyama I., Yamanaka K., Minematsu T., Mitsuoka K., Fushiki H., Miyoshi S., Sasamata M., Miyata K.Survivin supressant: a promising target for cancer therapy and pharmacological profiles of YM155[J]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2010,136 (4): 198–203.

[24] Rauch A, Hennig D, Schäfer C, Survivin and YM155: how faithful is the liaison[J]? Biochim Biophys Acta, 2014, 1845 (2): 202–220

[25] Wang J, Li W. Discovery of novel second mitochondria-derived activator of caspase mimetics as selective inhibitor of apoptosis protein inhibitors[J]. J Pharmacol Exp Ther, 2014, 349 (2): 319–329

[26] Xiao M, Wang J, Lin Z, Design, synthesis and structure-activity relationship studies of novel survivin inhibitors with potent anti-proliferative properties. PLoS One, 2015, 10 (6): e0129807

[27] Wang J, Chen J, Miller DD, Synergistic combination of novel tubulin inhibitor ABI-274 and vemurafenib overcome vemurafenib acquired resistance in BRAFV600E melanoma[J]. Mol Cancer Ther, 2014, 13 (1): 16–26

[28] Hwang DJ, Wang J, Li W, Structural optimization of indole derivatives acting at colchicine binding site as potential anticancer agents[J]. ACS Med Chem Lett, 2015, 6 (9): 993–997

[29] Akiyama S, Fojo A, Hanover JA, Isolation and genetic characterization of human KB cell lines resistant to multiple drugs[J]. Somat Cell Mol Genet, 1985, 11 (2): 117–126

[30] Robey RW, Shukla S, Finley EM, Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R))[J]. Biochem Pharmacol, 2008, 75 (6): 1302–1312

[31] Carmichael J, DeGraff WG, Gazdar AF, Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res, 1987, 47 (4): 936–942

[32] Verniest G, Wang X, De Kimpe N, Heteroaryl cross-coupling as an entry toward the synthesis of lavendamycin analogues: a model study. J Org Chem, 2010, 75 (2): 424–433

[33] Chouhan M, Kumar K, Sharma R, NiCl2 center dot 6H (2)O/NaBH4 in methanol: a mild and efficient strategy for chemoselective deallylation/debenzylation of aryl ethers[J]. Tetrahedron Lett, 2013, 54 (34): 4540–4543.

[34] Ludwig JA, Szakács G, Martin SE, Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer[J]. Cancer Res, 2006, 66 (9): 4808–4815

[35] Liu F, Xie ZH, Cai GP, The effect of survivin on multidrug resistance mediated by P-glycoprotein in MCF-7 and its adriamycin resistant cells[J]. Biol Pharm Bull, 2007, 30 (12): 2279–2283

[36] Shi Z, Liang YJ, Chen ZS, Overexpression of Survivin and XIAP in MDR cancer cells unrelated to P-glycoprotein[J]. Oncol Rep, 2007, 17 (4): 969–976

[37] Liu F, Liu S, He S, Survivin transcription is associated with P-glycoprotein/MDR1 overexpression in the multidrug resistance of MCF-7 breast cancer cells[J]. Oncol Rep, 2010, 23 (5): 1469–1475

Acknowledgment

This work supported by NIH/NCI grant 1R01CA 193609-01A1. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH/NCI. We thank Dr. Susan E Bates (Columbia University) for the SW620, SW620/Ad300 cell lines. We thank Dr. Shin-Ichi Akiyama (Kagoshima University, Japan) for the KB-3-1 and KB-C2 cell lines.

RIGHTS & PERMISSIONS

2017 2017 by the Journal of Biomedical Research. All rights reserved.